Study of Vepugratinib for advanced bladder or urinary tract cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic bladder or urinary tract cancer that cannot be removed with surgery
- Your cancer must have a specific change in the FGFR3 gene, found by testing a tumor or blood sample
- You must have measurable disease (tumors that can be tracked with scans)
- You must be able to care for yourself or need only some help (ECOG score 0-2)
- You must not have had any prior systemic treatment (like chemotherapy or immunotherapy) for advanced cancer
- You must have adequate organ function (kidney, liver, blood counts) and no severe eye or nerve problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
This study tests an oral medication (vepugratinib) that targets a specific gene change (FGFR3) found in some bladder cancers. It is for people with low-grade, non-invasive bladder cancer that has not spread into the muscle, to see if the drug can help control the cancer.
This expanded access program provides the investigational drug vepugratinib to people with advanced cancers (especially bladder cancer) that have a specific genetic change (FGFR3 mutation) and who have run out of standard treatment options. The goal is to give access to a potential new therapy outside of a clinical trial.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Hear when a new Carcinoma, Transitional Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.